1. Introduction {#s0005}
===============

Gaucher disease (GD) is a multisystemic disorder that results from the accumulation of undegraded glucocerebroside in lysosomes of tissue macrophages due to the deficiency of the enzyme β-glucocerebrosidase (EC 3.2.1.45) \[[@bb0005]\]. The deficiency of the enzyme is caused by autosomal recessive mutations in the *GBA1* (glucosidase beta acid) gene located on chromosome 1 (1q21) \[[@bb0010]\].

Gaucher disease is traditionally classified into three broad phenotypic categories: Type 1, a non-neuronopathic disease ranging from asymptomatic subjects to those who display childhood-onset disease. Type 2 GD is an acute neuronopathic form characterized by the early appearance of visceral signs, oculomotor abnormalities, brainstem involvement and limited survival to the first two or three years of life. Type 3 GD is a chronic neuronopathic disease characterized by neurologic symptoms that appear later in life. The appreciation that patients with type 1 may develop late-onset neurologic manifestations suggest that GD is a continuum of disease states \[[@bb0015],[@bb0020]\].

The incidence is 1/40,000 to 1/60,000 births in the general population, but it can reach 1/800 births in the Ashkenazi Jewish population \[[@bb0025]\]. The diagnosis relies on the measurement of β-glucocerebrosidase activity in leukocytes, fibroblasts or the recently developed screening tool using dry blood spots. Almost 300 mutations and polymorphisms in *GBA1* gene have been identified \[[@bb0020]\]. Treatment with macrophage-targeted mannose-terminated glucocerebrosidase enzyme replacement therapy (ERT) is the standard of care for patients with type 1 and 3 Gaucher disease \[[@bb0030]\]. Oral substrate reduction therapy in the form of Eliglustat has likewise been found to produce significant improvements in spleen and liver sizes, hematologic parameters, bone mineral density and disease biomarkers among adult patients with Gaucher disease type 1 \[[@bb0035]\].

In this review, we describe the clinical features, laboratory parameters and molecular characteristics of 14 Filipino patients with Gaucher disease, as well as the hematologic, skeletal, growth and neurologic responses of 6 patients who have undergone ERT.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

This study involved chart reviews of 14 Filipino patients confirmed to have Gaucher disease from 2003 to July 2017. The diagnosis was based on clinical findings and confirmed by low β-glucocerebrosidase activity in peripheral leukocytes or dried blood spots. The enzyme measurement was done at the National Taiwan University Hospital from 2004 to 2017. The first 2 patients diagnosed in 2003 had enzyme assays done at the National Referral Laboratory of the Women\'s and Children\'s Hospital in Adelaide Australia. The data during initial and follow up evaluations were gathered up to the latest month/year of consult. This study was approved by the institution\'s ethical review board (2017-265-01).

2.2. Clinical characteristics {#s0020}
-----------------------------

Data on the patients\' anthrophometrics, date of birth, date of diagnosis, date of the first symptoms and clinical features such as neurologic signs and organ measurements were obtained from the medical records of the Philippine General Hospital and the Institute of Human Genetics, National Institutes of Health-Manila (IHG-NIH). Hematologic, biochemical parameters and results of the ancillary investigations were also reviewed.

2.3. Mutation studies {#s0025}
---------------------

Twelve patients who are enrolled in RegistryNXT (<https://www.registrynxt.com>/) for Gaucher disease had the opportunity to have mutation testing done at the Molecular Development Laboratory of the University of Washington, USA after the families have undergone an informed consent process and pre genetic counseling at IHG-NIH. Sanger dideoxy sequencing of the entire coding region of the glucocerebrosidase (*GBA1*) gene was the reported method used for the identification of mutations. Post genetic counseling was given by geneticists at IHG-NIH upon receipt of the mutation results.

2.4. Method of data analysis {#s0030}
----------------------------

Quantitative patient characteristics are summarized by means and standard deviations (SDs). Qualitative characteristics such as clinical features and skeletal findings are presented as a frequency distribution.

3. Results {#s0035}
==========

3.1. Demographic, clinical and laboratory characteristics {#s0040}
---------------------------------------------------------

There were 14 patients with 3 sibling pairs from non-consanguineous pedigrees. There were 3 males and 11 females with ages that ranged from 1 month to 21 years. All were Filipinos except for Patient 12 and Patient 14. Five had type 1 disease who had no neurological involvement at diagnosis and latest follow up. Two patients (Patients 13 and 14) with type 2 GD presented with severe signs and symptoms early. Seven patients who manifested with seizures, developmental delay or abnormal eye movements were classified as type 3 ([Table 1](#t0005){ref-type="table"}). The mean age of onset of clinical manifestations for type 1 was 1.12 years (SD 0.56; 0.5--2 years) and the mean age for the confirmation of diagnosis was 3.35 years (SD 2.1; 0.25--5.5 years). For type 3, the mean age of onset of the signs and symptoms was 1.7 years (SD1.19; 1--4 years) and the diagnosis was confirmed at a mean of 3.9 years (SD 1.5; 2--6 years). Overall, it took an average of 2.2 years from the onset of clinical manifestations to confirmation of diagnosis for all types.Table 1Summary of clinical, biochemical and molecular characteristics.Table 1Pt \#Age at DxSexEthnicityPresenting clinical S/Sxβ- gluco cerebrosidaseGenotypeTypeOn/had ERTOutcome13.5yFFilipinoHS[a](#tf0005){ref-type="table-fn"} and bleeding390[b](#tf0010){ref-type="table-fn"}p.L483P/p.P358A3Started ERT at 3.7 yrs. old. Ongoing for 14 yrs.Alive24.5yFFilipinoHS [a](#tf0005){ref-type="table-fn"}0.88[c](#tf0015){ref-type="table-fn"}p.L483P/p.P358A3Started ERT at 5.5 yrs. old. Ongoing for 12 yrsAlive35yFFilipinoHS[a](#tf0005){ref-type="table-fn"}1.55[c](#tf0015){ref-type="table-fn"}p.F252I/p.F252I1Started ERT at 5.3 yrs. old. Ongoing for 6.6 yrsAlive42yFFilipinoHS[a](#tf0005){ref-type="table-fn"} and Seizures3.89[c](#tf0015){ref-type="table-fn"}p.N131S/p.P358A3Started ERT at 3.5 yrs. old and lasted for 2.7 yearsDied52yFFilipinoHS[a](#tf0005){ref-type="table-fn"} and Developmental delay3.26[c](#tf0015){ref-type="table-fn"}p.L483P/p.G241R/p.G241R3Started ERT at 2.6 yrs. old and lasted for 3.3 yrsDied63yMFilipinoHS[a](#tf0005){ref-type="table-fn"}1.23[c](#tf0015){ref-type="table-fn"}Not available1Started ERT at 4 yrs. old and lasted for a monthDied73 mFFilipinoHS[a](#tf0005){ref-type="table-fn"}0.04[d](#tf0020){ref-type="table-fn"}p.F252I/p.F252I1NoAlive86yMFilipinoHS[a](#tf0005){ref-type="table-fn"} and Esotropia0.36[d](#tf0020){ref-type="table-fn"}p.N131S/p.G416S3NoAlive95yFFilipinoSplenomegaly, Pallor, Esotropia and Seizures1.32[d](#tf0020){ref-type="table-fn"}p.N131S/p.G416S3NoAlive105.5yFFilipinoHS[a](#tf0005){ref-type="table-fn"}0.63[c](#tf0015){ref-type="table-fn"}p.L483P/p.L483P1NoAlive114yFFilipinoHS[a](#tf0005){ref-type="table-fn"}310 [b](#tf0010){ref-type="table-fn"}Not available1NoDied123yFIndianHS[a](#tf0005){ref-type="table-fn"}2.97[c](#tf0015){ref-type="table-fn"}p.N409S/p.L438P1NoLost to follow up132yFFilipinoHS[a](#tf0005){ref-type="table-fn"} and Ophthalmoplegia0.01[c](#tf0015){ref-type="table-fn"}IVS2 + 1 G \> A/p.F252I2NoDied141 mMFilipino/JapaneseSplenomegaly and Icthyosis0.12[d](#tf0020){ref-type="table-fn"}p.R519W/p.D257V2NoDied[^1][^2][^3][^4]

Hepatosplenomegaly as an initial presentation was seen in 12 patients (85.7%) while 2 patients presented with splenomegaly alone (Patients 9 and 14). Hepatosplenomegaly was accompanied by bleeding in 1 patient (7.14%), pallor in one (7.14%) and neurologic symptoms in 3 patients which manifested as either developmental delay, esotropia or seizures (21.4%). Of the type 2 patients, patient 13 presented with ocular abnormalities, hyperextension of the neck, developmental regression, microcephaly, spasticity, and tonic clonic seizures apart from hepatosplenomegaly. She succumbed at 2.5 years of age. Patient 14 had collodion ichthyosis at birth accompanied by hepatosplenomegaly, anemia and thrombocytopenia. He died at 2 months of age due to massive bleeding. At baseline, 9 (64.3%) patients were stunted (height for age z score −2) and 5 (35.7%) were underweight (weight for age z score −2). Patients 9 and 10 were splenectomized before the confirmation of diagnosis. The distribution of the other clinical manifestations are in [Table 2](#t0010){ref-type="table"}.Table 2Distribution of signs and symptoms according to the type of GD.Table 2Signs and symptomsTypes of Gaucher diseaseType 1 (n = 5)Type 2(n = 2)Type 3 (n = 7)TotalHepatosplenomegaly51612 (85.7%)Splenomegaly alone0112 (14.2%)HematologicalPallor52613 (92.8%)Bleeding2136 (42.8)Eye findingsStrabismus0134 (28.5%)Gaze Initiation Defect0145 (35.7%)NeurologicSeizures0055 (35.7%)Developmental delay0156 (42.8%)Intellectual disability0044 (28.5)Failure to thrive1045 (35.7%)Fatigue2046 (42.8)Bone Fracture0011 (7.14%)Bone Pain0011 (7.14%)Radiologic Bone Abnormalities[a](#tf0025){ref-type="table-fn"}3047 (63.6%)Erlenmeyer flask deformity325 (45.4%)Osteopenia112 (18.2%)Lytic changes11 (9.09%)Fracture11 (9.09%)[^5]

The initial mean hemoglobin for all types was 85.3 g/L (SD 35; range 10.9--16.4) and mean platelets were at 93 × 10^9^/L (SD 75; range 9--228 × 10^9^/L). Type 2 patients in this cohort were initially found to have normal hemoglobin and white blood cell count. Types 1 and 3 presented with anemia, thrombocytopenia and low WBC at baseline. AST that was minimally elevated in 10 of 12 patients with available data (83.3%) may not be liver specific. ALT was slightly elevated in 2 of the 12 (16.7%) ([Table 3](#t0015){ref-type="table"}). None were tested for hepatitis virus infection. Liver and spleen volumes were assessed by physical examination and ultrasound. Hepatomegaly was present in 12 of the 14 patients with a mean of 10 cm below the right costal margin (SD 6.7 cm; range 5--30 cm). On ultrasound, the liver span had an average of 11.9 cm at the mid-clavicular line (SD 2.4; 8.5--14.6 cm) and were all abnormal for age and sex. Splenomegaly affected all patients with a mean of 17.2 cm (SD 5.13; 10--27) below the left costal margin. Ultrasound splenic volume showed a mean of 504 mL at baseline (SD 232.6; range 170--897.5 mL) which were all above the upper limit based on weight \[[@bb0040],[@bb0045]\]. Eleven patients had skeletal survey done and 7 were found to have bone abnormalities. Erlenmeyer flask deformity was seen in 5 (45.5%), osteopenia in 2 (18.2%), lytic changes in 1 (9%) and fracture of the femoral bone in 1 (9%).Table 3Summary of baseline laboratory findings.Table 3Laboratory ParametersFrequencyMeanSDMinMaxHemoglobin (g/L)1485.335.053.0164.0 Type 1584.215.966.1109.0 Type 22144.028.3124.0164.0 Type 3783.319.353.0108.0Platelet (×10^9^/L)1492.975.49.0228.0 Type 15121.696.79.0226.0 Type 2271.037.045.097.0 Type 3778.669.231.0228.0WBC (×10^9^/L)148.04.92.719.7 Type 159.27.03.219.7 Type 2212.60.412.312.9 Type 375.92.82.710.1AST (IU/L)12103.2130.924.0513.0 Type 1389.95.384.094.0 Type 22291.0313.969.0513.0 Type 3755.121.324.091.0ALT (IU/L)1232.39.222.150.0 Type 1432.311.924.050.0 Type 2124.0------ Type 3733.58.522.149.0Chitotriosidase nmol/ml/h[a](#tf0030){ref-type="table-fn"}811,138.511,185.0322.527,128.9 Type 1317,238.814,448.1658.927,128.9 Type 2210,888.014,942.2322.521,454.0 Type 335204.12959.42344.48253.9[^6]

All had low β-glucocerebrosidase enzyme activity ([Table 1](#t0005){ref-type="table"}). Seven of the 14 patients had a bone marrow biopsy done which showed the characteristic "Gaucher cells". Chitotriosidase was elevated in 8 patients but 4 were noted to have deficient levels.

Only 6 of the 14 patients underwent compassionate enzyme replacement therapy (ERT). Two had type 1 GD and 4 had type 3 GD There was a delay of 1.2 years from the time of diagnosis to initiation of ERT. The mean age of starting ERT was 4.1 years (SD 1.1; 2.6--5.5 years) with a mean dose of 58.3 units/kg (SD 4.1). The mean duration of ERT at the time of this report was 6.45 years (SD 5.52; 0.08--14 years). Three patients (Patients 4, 5 and 6) died of pneumonia while on the 3rd year, 4th year and 1st month of ERT respectively. Two of the 6 patients, Patients 1 and 2, achieved normal growth parameters during the 2nd and 1st years of ERT respectively. One patient had normal height at the outset (Patient 5). Patient 3 who is on the 6th year of treatment continues to be stunted as of this report. Patients 4 and 6, who died while receiving treatment, did not achieve normal height. Normal hemoglobin \[[@bb0050]\] was achieved in Patients 1--5 at a mean of 7.8 months after initiation of ERT (SD 6.06). Patient 6 who died 1 month after ERT initiation had no normalization of hemoglobin. Platelet count increased by 1.5% in patients 1--5 at a mean of 6.2 months (SD 5.8), but normal levels (150-350 × 10^9^/L) were achieved in only 4 of them at a mean of 18 months (SD 5.03). Patients 5 and 6 remained to have low platelet counts at the time of their demise. Patients 1 and 2 achieved normal splenic volumes at a mean of 4.2 years (SD 2.2). Patient 3 had a 50% decrease in spleen volume after 3.75 years of treatment, however she remains to have an enlarged spleen even while on the 6th year of treatment. Patient 4 and 5 had enlarged spleen at the time of demise. All five patients achieved normal liver size by physical examination and ultrasound at a mean of 4.9 years after starting ERT (SD 2.8). Patients 1, 2 and 5 developed thoracic scoliosis while on the 14th, 12th, and 5th year of treatment respectively. Patients 3 and 4 still showed Erlenmeyer flask deformity after 6 and 2 years of ERT respectively.

There was note of increase in the frequency of seizures in two patients on ERT (Patients 4 and 5), while stabilization was seen in two (Patients 1 and 2). There was evolution of seizures to myoclonic jerks for Patient 4 on the 7th month of ERT. Patient 2 had cholelithiasis on the 11th year of treatment.

3.2. Mutation analysis of the GBA gene {#s0045}
--------------------------------------

Using the current nomenclature for *GBA1* mutations from the Human Genome Variation Society (<http://varnomen.hgvs.org>/), the most common mutant allele was L483P (previously L444), followed by F252I, P358A and G241R. IVS2 + 1 G \> A, N409S, R159W and G416S mutations were reported singularly. There were 3 patients who had the N131S mutation, a mutant allele that has only been reported among the Filipinos. Another novel mutation D257V was seen in one patient. The reported severe mutations L483P, F252I, G241R, G416S, R159W and IVS2 + 1 G \> A were seen in patients with Types 2 and 3 disease ([Table 1](#t0005){ref-type="table"}). However, the 2 patients homozygous for F252I (Patients 3 and 7) are clinically presenting with type 1 disease. N409S was found in patient 12 with Type 1 disease. The novel mutations N131S and D257V were found in patients who had Types 2 and 3 disease. Two patients (Patients 6 and 11) were not able to undergo mutation testing. They were classified to have type 1 disease; however, the possibility that they had severe mutations could not be discounted as their early demise and severe manifestations implied a possible type 3 GD.

4. Discussion {#s0050}
=============

This is the first review done among Filipino patients with Gaucher disease. The age of onset of clinical manifestations is in keeping with what has been reported in the literature. Most patients with type 1 disease have onset during the first decade of life, while patients with type 3 present at around 12 months old \[[@bb0055]\]. Despite early manifestations, diagnostic delay is one of the most significant observations in this study. Majority had severe manifestations early but the delay in diagnosis was most probably due to the failure to include GD in the differential diagnosis because of lack of awareness. Another reason could be the lack of local facilities for patients with rare diseases that can comprehensively assess these patients.

Hepatosplenomegaly was seen as the most common finding across all types in association with hematologic and bone abnormalities and is congruent with what have been reported in previous studies \[[@bb0060],[@bb0065]\]. Many of our patients presented with near normal liver function. The neurologic, ocular and other manifestations of our patients with types 2 and 3 GD are likewise similar with other registry reports \[[@bb0055],[@bb0070],[@bb0075]\].

The stunting in our patients could be due to the large mass of Gaucher\'s cells in the liver and spleen which exert an excessive metabolic burden leading to higher resting energy expenditure and increase in caloric requirements which manifested as a height-for-age z score less than zero \[[@bb0080]\]. The reported bone abnormalities such as osteopenia and lytic lesions are related to the accumulation of Gaucher cells in the bone marrow which lead to vascular occlusion and localized bone defects \[[@bb0005],[@bb0020]\].

The results of β glucocerebrosidase assay did not reliably enable prediction of disease severity or subtype \[[@bb0085]\]. Some of our patients who were classified as having a milder disease even had lower levels than patients with severe types. Our patients who had elevated chitotriosidase reflect the presence of lipid-laden macrophages due to GD \[[@bb0090]\]. However due to limited resources, this was not utilized to monitor the response to therapy. Four patients who were deficient in chitotriosidase were assumed to have the common 24 bp duplication polymorphism in the *CHIT* gene which is reported to be highest among Asians \[[@bb0095]\]. It was observed from the laboratory parameters of the 14 patients that hemoglobin levels for types 1 and 3 were almost similar, but platelets and WBC were higher in type 1. There is usually a significant correlation between the degree of splenomegaly and cytopenias but this proved to be clinically negligible \[[@bb0100]\]. It is difficult to make observations for other parameters according to type because of the small number of affected patients.

Only 6 of our patients were able to avail of compassionate ERT. Normal hemoglobin was achieved at an average of 7.8 months and is in keeping with a reported collaborative study that anemic patients usually normalized within 6--12 months \[[@bb0105]\]. All patients who underwent ERT had severe thrombocytopenia (\<120,000/μL) at baseline which improved 1.5 fold at a mean of 6 months. It is expected that platelet counts increase to 1.5-fold by year 1, and continue during the next 2 to 5 years, however restoration to normal is not usually expected \[[@bb0110]\]. The 2 patients who did not achieve normal platelets had significant splenomegaly at baseline. Although liver and spleen volumes were not routinely done during treatment monitoring, the liver sizes for 5 patients fell within the observed timeline for improvement of 5 years \[[@bb0115]\]. The decrease in spleen sizes have not been uniform among our patients on ERT. Three patients had slower response which could be due to prior splenic infarctions or fibrosis \[[@bb0115]\]. None had bone crisis or bone pain among our patients on ERT. However, 3 patients developed thoracic scoliosis and 2 were still found to have Erlenmeyer flask deformity years after initiating ERT. It has been reported that after 2 to 4 years of ERT, bone involvement improved in 30% to 40% of pediatric patients while there was progression in \<5% \[[@bb0110]\]. The scoliosis could be linked to abnormal bone density \[[@bb0120]\].

Cholelithiasis seen in Patient 2 has been reported to have increased prevalence in GD due to bile acid composition abnormalities \[[@bb0075]\]. The neurologic symptoms of our patients, as with other reports \[[@bb0125], [@bb0130], [@bb0135]\] were not reversed by ERT because the enzyme does not cross the blood-brain barrier.

The most common mutation seen in our population, L483P, is a mutation known to cause a severe disease \[[@bb0140], [@bb0145], [@bb0150]\]. It is also the most common mutation seen in other Asian populations \[[@bb0155], [@bb0160], [@bb0165]\]. In these populations, this mutant allele was associated with types 1,2 and 3 phenotypes in heterozygous or homozygous forms. In two of our patients who are siblings (Patients 1 and 2), L483P was seen in heterozygous combination with a rare allele P358A (previously P319A) of unknown severity \[[@bb0155]\]. Since these 2 patients presented with a chronic neuronopathic phenotype, P358A can be classified as severe. Patient 5 who had type 3 disease also had a severe allele G241R (previously G202R) in association with L483P. The parents\' genotype showed that the father is a carrier for L483P/wild type while the mother has G241R/wild type. The L483P and G241R mutations are known to occur in cis, and this is likely the case in this patient thereby accounting for the two G241R mutations as well as L483P. The "gene conversion" event between the active gene and pseudogene has probably been in the paternal side of the family for generations. G241R mutation destroys a Ncil restriction site in the *GBA* gene and has been reported in a patient who died of type 2 disease \[[@bb0140]\]. Patient 12 who had L483P as an heteroallele together with N409S (previously N307S) had a type 1 disease. N409S is known to be mild and even a severe or lethal mutation inherited with it results in type I disease \[[@bb0140],[@bb0170]\]. F252I (previously F213I) is a severe mutation seen among Asians with types 2 or 3 disease. Patients homozygous or heterozygous for this mutant allele presented primarily with oculomotor apraxia and mental retardation \[[@bb0130],[@bb0160]\]. There were 2 homozygotes for F252I in this cohort. They are siblings (Patients 3 and 7) who are currently classified as having type 1 disease because of the absence of ocular or neurologic abnormalities. F252I is a rare allele that was previously reported in a non-Jewish English family whose 2 affected children presented with GD type 1 \[[@bb0175]\]. In the Japanese patients, F252I mutation was also seen among those who were originally classified as having type 1 disease but eventually transitioned to type 3 \[[@bb0130]\]. Thus, these siblings should be closely monitored for subtle signs of type 3 disease during their clinical course. The other patient (Patient 13) carrying the F252I mutation who had type 2 GD was a heterozygote for a splicing null mutation IVS 2 + 1 G \> A that directs no functional enzyme activity \[[@bb0180]\]. The other patient with type 2 disease (Patient 14) had the severe mutation R159W (previously R120W) \[[@bb0145],[@bb0160],[@bb0165],[@bb0175]\]. This patient also carried a novel mutation D257V (previously D218V) which is predicted to be probably damaging to protein function with a score of 0.99 (<http://genetics.bwh.harvard.edu/pph2/bgi.shtml>). Three patients in this cohort had another novel mutation N131S (previously N92S) which had only been reported among Filipinos and is likewise predicted to be probably damaging with a score of 1.00 (<http://genetics.bwh.harvard.edu/pph2/bgi.shtml>). This mutation was found in association with G416S (previously G377S) that was previously reported to be seen in type 3 disease \[[@bb0150],[@bb0160]\] and with P358A. In the two patients who were compound heterozygotes for N131S and G416S, it is assumed that both gave rise to severe mutations leading to a neurologic phenotype.

In conclusion, our patients with Gaucher disease mostly had type 3 disease which is supported by the predominantly severe mutations noted in our population. Enzyme replacement therapy effectively improved the hematological impairments and hepatosplenomegaly, but due to the limited number of patients on ERT, deaths, and limitations on the use of recommended modalities for assessments, the results of the patterns of growth and skeletal manifestations may not accurately reflect the course of the disease. With the recent passage of the Rare Disease Act of the Philippines, it is hoped that physicians will be more aware of the presenting signs and symptoms of GD so that better access to diagnosis, and provision of a more comprehensive and sustainable treatment and monitoring will improve the neurologic and non-neurologic complications of the disease in this population.
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[^1]: Hepatosplenomegaly.

[^2]: Normal Value: 600--3200 pmole/min/mg protein; National Referral Laboratory, Adelaide; done in peripheral blood leukocytes.

[^3]: Normal Value: \>5.1 nmol/mg/prot/h; National Taiwan University Hospital; done in peripheral blood leukocytes.

[^4]: Normal Value: 1.8 umoles/L/h; National Taiwan University Hospital; done from blood spot aliquots.

[^5]: Two patients with type 2 GD and 1 with type 3 GD had no skeletal survey done.

[^6]: Chitotriosidase done in 12 patients but 4 were noted to have CHIT gene duplication.
